#USA #New York #Lawsuit #Unicycive Therapeutics #SueWallSt

Reminder for Unicycive Investors: Lead Plaintiff Deadline Approaches

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) faces serious scrutiny as a securities class action lawsuit unfolds. With the deadline for lead plaintiff applications set for November 2, 2026, all investors who bought shares between December 29, 2025, and June 29, 2026, need to be aware of their rights and the implications of the case.

On June 30, 2026, Unicycive’s stock plummeted by 39.1% in a single day, following the announcement of a second Complete Response Letter (CRL) from the FDA. This CRL was based on ongoing Good Manufacturing Practice (GMP) deficiencies at a third-party manufacturer, yet investors were allegedly not informed about the pre-existing compliance issues before the FDA's rejection.

Background on the Lawsuit

The lawsuit claims that Unicycive’s management misled shareholders regarding their compliance with FDA regulations and the status of their manufacturing processes. Specifically, it is alleged that the company failed to disclose that the third-party manufacturer's facility had not been inspected prior to their NDA resubmission.

Key Allegations Include:

• - Lack of Disclosure: Unicycive did not inform investors that the vendor's facility had not been inspected or audited for compliance with cGMP.
• - Misstatement of Progress: Management claimed they were making “significant progress” with the vendor without any verified inspection results.
• - Unsubstantiated Assurances: Investors were misled about the likelihood of timely FDA approval, with statements suggesting that everything was “on track” without revealing potential delays.

The failure to communicate these essential details not only resulted in an abrupt decline in stock value but also left investors vulnerable to significant losses. In light of these issues, shareholders must gather evidence of their purchases, including dates and quantities, to potentially join the lawsuit.

How to Participate

Investors are urged to act quickly to secure their rights. Those affected by the decline in UNCY's stock price can submit their information for a free evaluation. Even those who sold their shares but bought during the class period may still qualify for recovery.

SueWallSt, driven by Levi Korsinsky LLP, is at the forefront of this legal battle. Their record reflects success in securing substantial recoveries for shareholders and recognition in the securities litigation realm. The firm provides a solid footing for investors, ensuring that they can reclaim their losses effectively.

Frequently Asked Questions

• - What is a lead plaintiff?

The lead plaintiff is appointed by the court to represent the interests of the entire class of shareholders. This role typically goes to those with the most significant documented losses.

• - What costs are involved?

Participants in the lawsuit face no upfront costs; legal fees come from any settlements obtained and are typically subject to court approval.

• - What if I am not in the U.S.?

The lawsuit may also cover foreign investors who purchased shares on U.S. exchanges during the class period.

Conclusion

This is a pivotal moment for Unicycive Therapeutics investors. Facing serious allegations and a looming deadline, shareholders must stay informed and take action. For further advice or to find out more about eligibility, they can contact the legal team at SueWallSt. Time is running out for those wanting to secure their chance to recover losses stemming from this unsettling situation.